Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rhea N Coler

Showing results (41-50 of 132) with videos related to

Pageof 14
Sort By:
Infection and Immunity|July 16, 2002
Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasisRhea N Coler, Yasir A W Skeiky, Karen Bernards, et al.
The Journal of Infectious Diseases|February 1, 2015
Interferon γ and Tumor Necrosis Factor Are Not Essential Parameters of CD4+ T-Cell Responses for Vaccine Control of TuberculosisMark T Orr, Hillarie Plessner Windish, Elyse A Beebe, et al.
Vaccine|August 6, 2011
Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidateHillarie Plessner Windish, Malcolm S Duthie, Ayesha Misquith, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 3, 2014
Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosisMark T Orr, Gregory C Ireton, Elyse A Beebe, et al.
Tuberculosis (Edinburgh, Scotland)|November 14, 2022
Characterizing in vivo loss of virulence of an HN878 Mycobacterium tuberculosis isolate from a genetic duplication eventBryan J Berube, Sasha E Larsen, Matthew B McNeil, et al.
Msphere|December 9, 2024
Backtranslation of human RNA biosignatures of tuberculosis disease risk into the preclinical pipeline is condition dependentHannah Painter, Sasha E Larsen, Brittany D Williams, et al.
Biorxiv : the Preprint Server for Biology|July 1, 2024
Backtranslation of human RNA biosignatures of tuberculosis disease risk into the preclinical pipeline is condition dependentHannah Painter, Sasha E Larsen, Brittany D Williams, et al.
Frontiers in Immunology|July 5, 2024
Protective interplay: <i>Mycobacterium tuberculosis</i> diminishes SARS-CoV-2 severity through innate immune primingBrittany D Williams, Debora Ferede, Hazem F M Abdelaal, et al.
Vaccine|January 4, 2020
A phase 1 antigen dose escalation trial to evaluate safety, tolerability and immunogenicity of the leprosy vaccine candidate LepVax (LEP-F1 + GLA-SE) in healthy adultsMalcolm S Duthie, Aude Frevol, Tracey Day, et al.
Plos One|March 11, 2021
Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse modelSusan L Baldwin, Valerie A Reese, Sasha E Larsen, et al.
Pageof 14

Showing results (41-50 of 132) with videos related to

Sort By:
Pageof 14
Infection and Immunity|July 16, 2002
Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasisRhea N Coler, Yasir A W Skeiky, Karen Bernards, et al.
The Journal of Infectious Diseases|February 1, 2015
Interferon γ and Tumor Necrosis Factor Are Not Essential Parameters of CD4+ T-Cell Responses for Vaccine Control of TuberculosisMark T Orr, Hillarie Plessner Windish, Elyse A Beebe, et al.
Vaccine|August 6, 2011
Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidateHillarie Plessner Windish, Malcolm S Duthie, Ayesha Misquith, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 3, 2014
Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosisMark T Orr, Gregory C Ireton, Elyse A Beebe, et al.
Tuberculosis (Edinburgh, Scotland)|November 14, 2022
Characterizing in vivo loss of virulence of an HN878 Mycobacterium tuberculosis isolate from a genetic duplication eventBryan J Berube, Sasha E Larsen, Matthew B McNeil, et al.
Msphere|December 9, 2024
Backtranslation of human RNA biosignatures of tuberculosis disease risk into the preclinical pipeline is condition dependentHannah Painter, Sasha E Larsen, Brittany D Williams, et al.
Biorxiv : the Preprint Server for Biology|July 1, 2024
Backtranslation of human RNA biosignatures of tuberculosis disease risk into the preclinical pipeline is condition dependentHannah Painter, Sasha E Larsen, Brittany D Williams, et al.
Frontiers in Immunology|July 5, 2024
Protective interplay: <i>Mycobacterium tuberculosis</i> diminishes SARS-CoV-2 severity through innate immune primingBrittany D Williams, Debora Ferede, Hazem F M Abdelaal, et al.
Vaccine|January 4, 2020
A phase 1 antigen dose escalation trial to evaluate safety, tolerability and immunogenicity of the leprosy vaccine candidate LepVax (LEP-F1 + GLA-SE) in healthy adultsMalcolm S Duthie, Aude Frevol, Tracey Day, et al.
Plos One|March 11, 2021
Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse modelSusan L Baldwin, Valerie A Reese, Sasha E Larsen, et al.
Pageof 14